1. Home
  2. REVBW vs GRABW Comparison

REVBW vs GRABW Comparison

Compare REVBW & GRABW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVBW
  • GRABW
  • Stock Information
  • Founded
  • REVBW N/A
  • GRABW 2012
  • Country
  • REVBW United States
  • GRABW Singapore
  • Employees
  • REVBW 9
  • GRABW N/A
  • Industry
  • REVBW Biotechnology: Pharmaceutical Preparations
  • GRABW Business Services
  • Sector
  • REVBW Health Care
  • GRABW Consumer Discretionary
  • Exchange
  • REVBW Nasdaq
  • GRABW Nasdaq
  • Market Cap
  • REVBW N/A
  • GRABW N/A
  • IPO Year
  • REVBW 2020
  • GRABW N/A
  • Fundamental
  • Price
  • REVBW $0.02
  • GRABW $0.55
  • Analyst Decision
  • REVBW
  • GRABW
  • Analyst Count
  • REVBW 0
  • GRABW 0
  • Target Price
  • REVBW N/A
  • GRABW N/A
  • AVG Volume (30 Days)
  • REVBW N/A
  • GRABW 54.7K
  • Earning Date
  • REVBW N/A
  • GRABW 02-21-2025
  • Dividend Yield
  • REVBW N/A
  • GRABW N/A
  • EPS Growth
  • REVBW N/A
  • GRABW N/A
  • EPS
  • REVBW N/A
  • GRABW N/A
  • Revenue
  • REVBW N/A
  • GRABW $2,686,000,000.00
  • Revenue This Year
  • REVBW N/A
  • GRABW N/A
  • Revenue Next Year
  • REVBW N/A
  • GRABW N/A
  • P/E Ratio
  • REVBW N/A
  • GRABW N/A
  • Revenue Growth
  • REVBW N/A
  • GRABW 21.65
  • 52 Week Low
  • REVBW N/A
  • GRABW $0.15
  • 52 Week High
  • REVBW N/A
  • GRABW $0.59
  • Technical
  • Relative Strength Index (RSI)
  • REVBW N/A
  • GRABW 62.13
  • Support Level
  • REVBW N/A
  • GRABW $0.42
  • Resistance Level
  • REVBW N/A
  • GRABW $0.59
  • Average True Range (ATR)
  • REVBW 0.00
  • GRABW 0.07
  • MACD
  • REVBW 0.00
  • GRABW 0.01
  • Stochastic Oscillator
  • REVBW 0.00
  • GRABW 80.28

About REVBW Revelation Biosciences Inc. Warrant

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About GRABW Grab Holdings Limited Warrant

Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore and Malaysia contributed 58% of revenue as of end-2021. Grab's main competitors in Southeast Asia are Foodpanda and Gojek, the ride-sharing arm of GoTo. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.

Share on Social Networks: